Webinar: When, Why, and How to Think about Medicines for Behavior in Autism
Date Published: July 1, 2022
In this recorded webinar, Jeremy Veenstra-VanderWeele, M.D., Ph.D., reviews the science on what is known about the use of medicines for treating behavior in autism.
Who is Jeremy Veenstra-VanderWeele?
Jeremy Veenstra-VanderWeele is a child and adolescent psychiatrist who uses molecular and translational neuroscience research tools in the pursuit of new treatments for autism spectrum disorder (ASD) and pediatric obsessive compulsive disorder (OCD). His molecular neuroscience laboratory at Columbia University and the New York State Psychiatric Institute focuses on genetic mouse models with abnormal social or repetitive behavior. His clinical/translational research program at the NewYork-Presbyterian Hospital Center for Autism and the Developing Brain studies potential treatments for ASD and related genetic syndromes. Veenstra-VanderWeele serves as an Associate Editor of Autism Research, the Journal of the International Society for Autism Research. He currently chairs the NIH Developmental Brain Disorders Study Section and serves on advisory boards for the Simons Foundation and Autism Speaks. His work has garnered multiple awards, including the Blanche Ittelson Award for Research in Child and Adolescent Psychiatry from the American Psychiatric Association.